- Home
- MODD vs FGEN Comparison
MODD vs FGEN Comparison
Compare MODD & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MODD
- FGEN
- Stock Information
- Founded
- MODD 1998
- FGEN 1993
- Country
- MODD United States
- FGEN United States
- Employees
- MODD N/A
- FGEN N/A
- Industry
- MODD Industrial Specialties
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- MODD Health Care
- FGEN Health Care
- Exchange
- MODD Nasdaq
- FGEN Nasdaq
- Market Cap
- MODD 35.5M
- FGEN 33.5M
- IPO Year
- MODD N/A
- FGEN 2014
- Fundamental
- Price
- MODD $0.89
- FGEN $0.29
- Analyst Decision
- MODD
- FGEN Strong Buy
- Analyst Count
- MODD 0
- FGEN 1
- Target Price
- MODD N/A
- FGEN $10.00
- AVG Volume (30 Days)
- MODD 155.4K
- FGEN 1.2M
- Earning Date
- MODD 02-13-2025
- FGEN 05-05-2025
- Dividend Yield
- MODD N/A
- FGEN N/A
- EPS Growth
- MODD N/A
- FGEN N/A
- EPS
- MODD N/A
- FGEN N/A
- Revenue
- MODD N/A
- FGEN $29,621,000.00
- Revenue This Year
- MODD N/A
- FGEN $232.81
- Revenue Next Year
- MODD N/A
- FGEN $9.16
- P/E Ratio
- MODD N/A
- FGEN N/A
- Revenue Growth
- MODD N/A
- FGEN N/A
- 52 Week Low
- MODD $0.68
- FGEN $0.18
- 52 Week High
- MODD $2.65
- FGEN $1.74
- Technical
- Relative Strength Index (RSI)
- MODD 43.99
- FGEN 41.77
- Support Level
- MODD $0.79
- FGEN $0.23
- Resistance Level
- MODD $0.95
- FGEN $0.31
- Average True Range (ATR)
- MODD 0.10
- FGEN 0.03
- MACD
- MODD -0.01
- FGEN 0.01
- Stochastic Oscillator
- MODD 28.42
- FGEN 55.45
About MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.